Skip to content
DataLookout
Menu

NCT05796206

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words Show 6 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Feb 2026 to Nov 21, 2024
    • Enrollment target: estimated 120 to confirmed 123
    • Study completion date changed from estimate of Jul 2026 to Jul 2, 2026
    • Secondary endpoints: details revised at 1 of 13 entries
    • Site details revised
  2. Notable Phase: Phase 2/3 to Phase 2v4 Show 7 more changesShow less
    • Enrollment target: 200 to 120
    • Eligibility criteria expanded, about 51 words
    • Primary endpoint revised
    • Trial status: Recruiting to Active, Not Recruiting
    • Secondary endpoints: 10 to 13
    • Site details revised
    • Study title expanded, about 2 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2023 to May 26, 2023
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Part A and Part B:Percentage of participants achieving SRI-4 at Week 12
Timeframe: at Week 12

Secondary (13)

Part A and Part B:Proportion of participants achieving SRI-4 at Week 52
Part A and Part B:Proportion of participants achieving SRI-4 at Week 24
Part A and Part B:Proportion of participants achieving SRI-4 at Week76
Part A and Part B:Change From Baseline in 24-hour urine protein in participants with elevated baseline urine protein (24-hour urine protein ≥ 0.5g) at Week 24,52,76
Part A and Part B:Percentage of participants who achieved or maintained a prednisone dose of ≤7.5 mg/day (or equivalent dose) during Weeks 40 to 52
Show 8 moreShow less
Part A and Part B:Change From Baseline in EuroQol- 5 Dimension (EQ-5D) at Week 24, 52, 76
Part A and Part B:Change From Baseline in Serum Immunoglobulin Levels at Week 24 Change from baseline in the serum levels of IgG, IgA, IgM
Part A and Part B:Change From Baseline in biomarkers associated with disease anti-dsDNA ,complement component 3 (C3), and complement component 4 (C4)
Part A and Part B:Percentage of Participants with Adverse Events
Part A: Pharmacokinetic(PK) Parameters: AUC
Part A: Pharmacokinetic(PK) Parameters:Cmax
Part A and Part B: Pharmacodynamics(PD) characteristics:summarizing the changes in the absolute counts and percentages of peripheral blood CD19⁺ B cells, CD3⁺CD4⁺ T cells, CD3⁺CD8⁺ T cells, NK cells, CD19⁺CD27⁺ B cells, and CD19⁺CD27- naïve B cells
Part Aand Part B: Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL62

Arms and interventions

MIL62(Part A and B)Experimental
Placebo (Part A and B)Placebo comparator

Drugs: MIL62, placebo

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, China